abstract OBJECTIVE: The purpose of this work was to collect data regarding vaccine prices and reimbursements in private practices. Amid reports of physicians losing money on vaccines, there are limited supporting data to show how much private practices are paying for vaccines and how much they are being reimbursed by third-party payers.
Spurred by recent national recommendations of expensive vaccines, [1] [2] [3] [4] anecdotal reports indicate that physicians in private practice are facing financial difficulties related to providing childhood/adolescent immunizations. [5] [6] [7] [8] [9] Concerns among physician organizations (eg, the American Academy of Pediatrics) and other stakeholders have led to discussions regarding the scope of the problem and possible solutions. [10] [11] [12] However, surprisingly little is known regarding the financial burden of providing childhood vaccines in private practices.
Understanding vaccine financing at the practice level requires data on a practice's costs of providing vaccines and the level of reimbursement that the practice receives from insurance carriers. The most readily observable cost is the direct cost of purchasing the vaccines (ie, purchase price). Published data on the prices paid for vaccines at the private-practice level are not available. However, national vaccine price data can serve as points of reference, including the public-sector price, the average sales price (ASP), and the average wholesale price (AWP). Public-sector prices are negotiated annually with vaccine manufacturers by the Centers for Disease Control and Prevention (CDC) for the federal vaccine contract, 4 which is used by government immunization programs to purchase vaccine at reduced rates. ASPs are publicly available data collected from vaccine manufacturers by the US Centers for Medicare and Medicaid Services and are based on quarterly reports of the prices of vaccines sold in that quarter. 13 AWPs are proprietary data licensed by vendors; the AWP for each vaccine incorporates the national average price determined by its manufacturer plus a 20%-25% markup. 14 How actual prices paid by private practices compare with these reference price data are unknown. Also unknown is the extent to which practices use group purchasing organizations and other strategies to minimize the prices that they pay.
With regard to reimbursement for vaccine purchase, we did not find any existing studies documenting reimbursement levels in private practices. US Centers for Medicare and Medicaid Services uses ASPs to set Medicare vaccine payments (currently at 106% of ASP). 15 Many private insurers are thought to set their reimbursement rates as a percentage of AWPs or ASPs, including rates for pediatric vaccines, but contractual reimbursement levels are considered proprietary data.
In addition to the purchase of vaccines, practices face many other costs associated with providing vaccines. Personnel costs are composed of physician and other staff time for tasks such as ordering vaccines, administering vaccines, counseling patients, and entering data into registries or medical charts. Other costs include vaccine storage, insurance against vaccine loss, and medical supplies. Some studies have attempted to quantify other costs associated with provision of vaccines, but methodologic issues make such estimates difficult. 16, 17 Reimbursement for these costs is generally done as a separate vaccine administration fee. To address the lack of data regarding vaccine costs and reimbursements in private practices, this study sought to collect and compare actual price and reimbursement data from a sample of private practices.
METHODS

Sample
The survey was conducted by using a convenience sample of practices in 5 states (California, Georgia, Michigan, New York, and Texas). States were selected to reflect regional variation and a mix of urban and rural areas. Excluded were states with universal purchase programs, where the vast majority of childhood vaccines are supplied to private practices by the state.
The sampling was based on physician specialty, metropolitan statistical area (MSA) status, and practice size. The goal was to achieve a sample of 15 pediatric or family physician practices (5 small, 5 medium, and 5 large practices) from both MSA and non-MSA areas of each state. Excluded were practices associated with academic medical centers and practices that do not administer vaccines to privately insured patients. In addition, only 1 practice within the same practice network could be selected for the sample.
MSA and non-MSA areas in each state were determined from US Census data. 18 Publicly available business directories were used to identify pediatric and family physician practices in these areas and to collect data on the number of physicians at each practice, as well as practice contact information. Practice size was categorized as small (1-2 physicians), medium (3-5 physicians), and large (Ն6 physicians).
A research assistant contacted each practice by telephone to determine which physician(s) was involved in decision-making for the practice (eg, "lead" physician, managing partner, or medical director). Our initial survey communication was directed to this physician.
Survey Design
We developed a 10-page, 20-question survey to collect data on a practice's vaccine purchases and the reimbursements that it receives for vaccine purchase and administration from its 3 most common, non-Medicaid payers. Question formats were a mix of openended and fixed-choice questions.
For vaccine purchase, a grid collected detailed data on the most recent order for each of the universally recommended vaccines on the childhood immunization schedule, including the vaccine brand, order date, number of doses or packages, packaging type, total number of doses, total price paid, whether purchased from the manufacturer or through a distributor, the estimated ordering frequency, and availability of return privileges. Additional questions explored participation in a purchasing cooperative or buying group and other payment policies or discounts not reflected in the prices paid.
For reimbursements, respondents were asked to provide data for each of their practice's 3 most common, nonMedicaid payers; determining the "most common" payers was left to the discretion of the practices, and we did not ask for payer names. Data collected included specific reimbursement per dose for each vaccine and specific reimbursement for administration of the first and subsequent doses of vaccines per visit (based on Current Procedural Terminology codes 90471 and 90472). Additional questions explored recent changes in reimbursement policies, provisions included in payer contracts (eg, payment formulas for vaccine cost reimbursement), and whether vaccine reimbursement issues had ever compelled a practice to terminate a relationship with a payer or stop administering vaccines to patients enrolled in a certain plan. We made minor refinements to the instrument on the basis of pilottest feedback; pilot-test data were included in the analyses. The institutional review board of the University of Michigan Medical School approved this study.
Survey Administration
An introductory packet was sent via priority mail to the contact physician identified for each practice. The packet included a personalized cover letter signed by the lead investigator (Dr Freed); a personalized letter of support for the study signed by the executive director of the American Academy of Pediatrics; a confidentiality agreement signed by all of the study team members to provide written assurance that confidential data would be handled appropriately; a postagepaid postcard on which the contact physician could indicate his or her interest in participating and list the most appropriate staff person(s) within the practice for collecting vaccine purchase and reimbursement data; and a small monetary incentive. Physicians who did not return the postcard within a month were contacted by telephone to request their participation.
The persons identified by responding physicians were then contacted by telephone and the survey instrument transmitted to them, typically by fax. Participants were given the option of returning the survey by fax, followed by a telephone call to review their responses, or completing the survey by telephone. Given the detailed nature of the data collection form, practice staff had to refer to multiple data sources (eg, invoices for vaccine orders and payer billing records), and Ͼ1 staff person was typically involved (eg, nurse responsible for vaccine ordering and office manager). Practices often needed many weeks to complete the survey and were typically contacted numerous times by the study team to encourage and assist them in the data collection process. We contacted a total of 387 practices to participate in the study. Practices that were able to complete the survey were sent a gift basket in appreciation of their efforts. Data were collected from April to December 2007.
Data Analysis
For each vaccine, we calculated the price per dose paid for each practice and then calculated the mean, median, maximum, and minimum prices across practices. We also calculated the mean, median, maximum, and minimum reimbursements for vaccine purchase from the most common payer and for the 3 most common payers across practices. Next, we calculated a "net yield" for each vaccine at each practice (ie, the reimbursement for vaccine purchase minus the price per dose paid) and calculated the mean, median, maximum, and minimum net yields across practices. The mean, median, maximum, and minimum administration fee reimbursements for the first and subsequent doses were also calculated across practices.
Prices per dose and vaccine purchase reimbursement levels that were Ͼ2 SDs from the mean were considered "outliers." We recontacted practices to verify or correct these data; in the few cases where outliers could not be verified, the data were excluded from the analyses. Across all of the price and payer data points per vaccine, an average of 4 were excluded (range: 0 -9 data points).
For each vaccine, stratified analyses also were conducted. Price and net yield data were stratified according to practice size, MSA status, and participation in a purchasing cooperative or buying group, whereas reimbursement data were stratified according to practice size and MSA status. Means were calculated and differences across strata observed.
All of the analyses were conducted using Microsoft Excel 2002 SP3 (Redmond, WA). Although data calculations included both the mean and the median, the numbers were consistently similar, so only the mean is reported here. Similarly, only results of the reimbursement-related calculations for the most common payer (versus also presenting results for the 3 most common payers) are provided because of space constraints and to illustrate the most frequent financial situation encountered by practices.
RESULTS
Respondent Characteristics
Eligible surveys were received from 76 practices. The majority of practices were located in MSA areas and included Ն3 physicians ( Table 1) . The majority reported participating in a purchasing cooperative or buying group for vaccines for at least some of the vaccines that they purchase.
Vaccine Purchase Prices
Price-per-dose data are shown in Table  2 . The difference between the maximum and minimum price per dose across practices ranged from $4 for Boostrix to more than $30 for Pediarix, Havrix, and ProQuad.
For purposes of comparison, data on the public-sector price, ASP, and AWP are shown in Table 2 . Some practices described other types of discounts or rebates that are available to them. Two thirds of the practices (n ϭ 54) reported a "prompt-pay" discount, in which a small percentage discount is applied if the practice pays within a certain time frame. Others included small percentage discounts for placing vaccine orders online (16% [n ϭ 13]), promotional pricing such as at "back-to-school" time (23% [n ϭ 18]), and volume discounts (35% [n ϭ 28]). Discounts and rebates applied after an order was filled (eg, prompt-pay discounts) are typically not reflected in the data on prices paid.
Vaccine Purchase Reimbursement
Data on reimbursement for vaccine purchase from respondents' most common, non-Medicaid payer demonstrate a wide range of reimbursements across practices (Table 3) . Differences between the maximum and minimum reimbursement amounts across participating practices ranged from $8 to more than $80. Mean reimbursements ranged from ϳ80% of ASP for all of the diphtheria-tetanusacellular pertussis brands and Յ123% of ASP. Mean reimbursements for all vaccines were at or above AWP. Mean reimbursements for vaccine purchase by the most common payer were higher in larger practices for 17 of 21 vaccines and those located in MSAs for 17 of 21 vaccines. Table 4 presents data for the net yield (reimbursement minus price paid) per dose for the participating practices.
Net Yield for Vaccine Purchase
Mean net yield varied across vaccines from a low of approximately $3 to more than $24 for. The range of net yield across practices varied widely, from $10 to $90. For 15 of the 21 specific vaccines analyzed, Ն1 practice reported that the vaccine purchase price exceeded the most common payer reimbursement; this situation was most common. On the basis of stratified calculations, mean net yield was higher in practices that were larger for all but 1 vaccine, those located in MSAs for all but 2 vaccines, and those participating in purchasing cooperatives for 14 of 21 vaccines.
Administration Fee Reimbursement
Reimbursement from the most common payer for first dose vaccine administration ranged from $0.00 to $26.55, with a mean of $16.39 (Table 5) . Reimbursement for subsequent doses was typically lower, with a mean of $11.17.
Other Reimbursement Issues
Most respondents reported that their contract with their most common payer includes separate payments for vaccine purchase and administration (Table 6 ) and that the majority of these contracts contain specific language addressing the method and time frame for payment. Twenty-four percent of practices (n ϭ 18) have either discontinued a relationship with a payer because of its level of payment for vaccine purchase or administration fees or stopped administering vaccines to patients in a certain plan because of the plan's level of payment for vaccine purchase or administration fees.
DISCUSSION
The key finding from this study is the wide range in both the purchase price and reimbursement for vaccines. This study is the first to document this vari- DTaP indicates diphtheria-tetanus-acellular pertussis; IPV, inactivated polio vaccine; MMR, measles-mumps-rubella; Hib, Haemophilus influenzae type b; Hep, hepatitis; PCV7, heptavalent pneumococcal conjugate vaccine; V, varicella; HPV, human papillomavirus; MCV4, meningococcal conjugate vaccine; TdaP, tetanus-diphtheria-acellular pertussis. Data show the vaccine purchase reimbursement for most common payer summarized across practices.
ation, and the study team found the extent and multimodal nature of the variation to be surprising. The variation in prices paid across practices for the same vaccine was Ͼ100% in several cases, and a few practices reported paying less than the public-sector price for some vaccines. The difference in reimbursements across practices was also Ͼ100% in some instances for the same vaccine. We found significant variation in the administration fees paid by private insurers as well.
In comparing reimbursements to prices paid, we found variation across vaccines within a practice and across practices for the same vaccine. For example, some practices in our study had a positive net yield of up to almost $39.00 per dose on the purchase of heptavalent pneumococcal conjugate vaccine, whereas 11% of the practices in our study had a negative net yield on the same vaccine.
These data cannot be used to say whether practices are making a profit or losing money on vaccines. We did not collect data on overall costs to the practice of purchasing and administering vaccines, on reimbursements from all payers, or on the proportion of children insured by each payer. However, these data do illustrate the complexity of vaccine financing at the private-practice level. The variation is the product of many factors, some of which individual practices may be able to influence and some they may not.
One implication of this study is that it is important for individual practices to get a detailed understanding of their own costs and reimbursements for vaccines, particularly given the expanding schedule of vaccines recommended for children and adolescents and increasing vaccines prices. On the vaccine purchase side, practices should explore opportunities to achieve discounts off the price of vaccines, such as participating in a purchasing cooperative, as 54% of the practices in this study do for at least some of the vaccines that they purchase. For reimbursements, practices should look across their entire payer Specific language addressing timely response to vaccine price increases 17 (13) Specific language addressing timely response to revised vaccine recommendations 17 (13) mix and identify low reimbursements for a particular vaccine or payers with low reimbursements overall. Although more economic impact will be felt by a practice as a consequence of reimbursement rates from their most common payer, the overall financial impact will be the sum of all of the payers. With an understanding of how reimbursements vary across payers and vaccines, practices will be in a better position to negotiate higher rates.
Clearly, significant improvements in payment and reimbursement policies cannot be achieved solely through the efforts of individual practices, and vaccine financing issues are receiving significant attention from physician organizations at the national level. 
CONCLUSIONS
This study was designed to collect basic descriptive data on the prices paid by private practices for vaccines and the reimbursements they receive from payers. Our results indicate that there is a wide range of prices paid by practices for the same vaccine product and in the reimbursement for vaccines and administration fees by payers. At the practice level, this variation underscores the need for practices to be cognizant of their own costs and reimbursements for vaccines and to actively seek opportunities to lower their expenditures and to increase their reimbursements. On a broader level, these data should help inform the continuing discussions by immunization policy-makers and other stakeholders to address vaccine financing concerns.
